Want to see SION full AI Analyst Report?
Top Page
Sionna Therapeutics, Inc.
(NASDAQ:SION)
Select Model
Select Model
Rating:55Neutral
Price Target:
$49.00
▲(7.22% Upside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and sustained cash burn), partially offset by a strong low-debt balance sheet. Technicals are a meaningful positive with price above major moving averages and healthy (not extreme) momentum. Valuation remains a drawback due to negative earnings and no dividend support.
Positive Factors
Low leverage
Very low debt relative to equity gives durable financial flexibility for a development-stage biotech. It reduces interest burden and bankruptcy risk, allowing the company to fund ongoing R&D or pursue partnerships without immediate pressure to service high leverage, supporting multi-quarter runway.
Negative Factors
Pre-revenue profile
No product revenue means the company's economics depend entirely on successful clinical outcomes or external financing. This creates persistent revenue execution risk: until commercialization, the business cannot generate operating cash inflows to sustainably fund R&D or reduce reliance on capital markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low debt relative to equity gives durable financial flexibility for a development-stage biotech. It reduces interest burden and bankruptcy risk, allowing the company to fund ongoing R&D or pursue partnerships without immediate pressure to service high leverage, supporting multi-quarter runway.
Read all positive factors
Sionna Therapeutics, Inc. (SION) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.13B
Dividend YieldN/A
Average Volume (3M)433.16K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS Growth-27.48%
CountryUS
Employees59
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.18
Shares Outstanding45,150,330
10 Day Avg. Volume474,586
30 Day Avg. Volume433,158
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$51.71Price Target Upside13.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.6
Revenue Forecast (FY)N/A
Sionna Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal funct...
How the Company Makes Money
null...
Sionna Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -306.00K | -647.00K | -668.00K | 0.00 | 0.00 |
| EBITDA | -95.61M | -74.62M | -61.02M | -46.68M | -40.12M |
| Net Income | -97.38M | -75.27M | -61.69M | -47.26M | -40.24M |
Balance Sheet | |||||
| Total Assets | 283.25M | 325.95M | 185.75M | 51.95M | 87.37M |
| Cash, Cash Equivalents and Short-Term Investments | 211.03M | 235.88M | 147.54M | 38.52M | 82.61M |
| Total Debt | 8.07M | 8.68M | 9.75M | 10.48M | 0.00 |
| Total Liabilities | 17.47M | 19.12M | 349.46M | 166.83M | 157.29M |
| Stockholders Equity | 265.77M | 306.83M | -163.71M | -114.88M | -69.92M |
Cash Flow | |||||
| Free Cash Flow | -76.21M | -66.67M | -52.81M | -44.81M | -37.94M |
| Operating Cash Flow | -75.92M | -66.30M | -52.79M | -43.70M | -36.07M |
| Investing Cash Flow | 91.98M | -118.75M | -126.91M | 27.35M | -29.26M |
| Financing Cash Flow | 6.28M | 205.71M | 178.97M | 31.00K | 110.86M |
Sionna Therapeutics, Inc. Technical Analysis
Positive
45.70
Price Trends
32.75
Positive
26.82
Positive
Market Momentum
1.96
Negative
71.28
Negative
70.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SION, the sentiment is Positive. The current price of 45.7 is above the 20-day moving average (MA) of 37.46, above the 50-day MA of 32.75, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 1.96 indicates Negative momentum. The RSI at 71.28 is Negative, neither overbought nor oversold. The STOCH value of 70.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SION.
Sionna Therapeutics, Inc. Risk Analysis
Sionna Therapeutics, Inc. disclosed 76 risk factors in its most recent earnings report. Sionna Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sionna Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.80B | -10.20 | -59.36% | ― | -83.20% | -439.48% | |
56 Neutral | $2.26B | -13.72 | -55.69% | ― | ― | 51.42% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $2.13B | -24.42 | -27.31% | ― | ― | -27.48% | |
53 Neutral | $1.49B | -3.02 | -57.27% | ― | 45.04% | 32.42% | |
48 Neutral | $1.57B | 23.97 | 4.89% | ― | -2.20% | 77.51% | |
44 Neutral | $2.63B | -39.88 | -7.70% | ― | 157.97% | 86.11% |
* General Sector Average
SION
Sionna Therapeutics, Inc.
47.34
30.36
178.80%
SRPT
Sarepta Therapeutics
15.93
-0.33
-2.03%
NTLA
Intellia Therapeutics
10.97
-0.40
-3.52%
STOK
Stoke Therapeutics
31.93
18.76
142.44%
BEAM
Beam Therapeutics
27.07
8.77
47.92%
AMLX
Amylyx Pharmaceuticals Inc
21.85
13.66
166.79%
Sionna Therapeutics, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Sionna Stockholders Reelect Directors, Ratify Deloitte as Auditor
Positive
Jun 18, 2026
At its June 17, 2026 Annual Meeting of Stockholders, Sionna Therapeutics, Inc. reported that a quorum was present, with 45,142,330 common shares outstanding as of the April 21, 2026 record date, and stockholders voted on the election of four Class...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.